Dibble, Kate E.
Rosenberg, Shoshana M.
Zheng, Yue
Sella, Tal
Poorvu, Philip
Snow, Craig
Darai, Sonja
Rene, Christamar
Mack, Jennifer W.
Partridge, Ann H. http://orcid.org/0000-0002-4722-4824
Funding for this research was provided by:
Helen Gurley Brown Foundation at Dana-Farber Cancer Institute
Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center
Breast Cancer Research Foundation
Article History
Received: 20 December 2023
Accepted: 7 May 2024
First Online: 10 May 2024
Declarations
:
: Dr. Kate Dibble has no conflicts of interest to disclose. Dr. Shoshana Rosenberg reports grant funding from Pfizer/Conquer Cancer. Yue Zheng has no conflicts of interest to disclose. Dr. Tal Sella reports honorarium from Roche, Novartis, and Eli Lilly; advisor for Eli Lilly; and travel support from Gilead and Astrazenica. Dr. Poorvu has no conflicts of interest to disclose. Craig Snow has no conflicts of interest to disclose. Sonja Darai has no conflicts of interest to disclose. Christamar Rene has no conflicts of interest to disclose. Dr. Jennifer Mack has no conflicts of interest to disclose. Dr. Partridge reports receiving royalties from Wolters Kluwer for authorship of UpToDate and has received research funding from Novartis.
: This study was reviewed and approved by the Dana-Farber Cancer Institute Institutional Review Board (IRB#20–124) in accordance with the Declaration of Helsinki.
: Study coordinators reviewed the consent form, verifying interest, and confirming eligibility with each potential participant. This study was granted a waiver of documentation of consent. Passive consent was granted by marking a check box on REDCap stating they were willing to participate in the study.
: Not applicable.